All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Pharma marketing company Solstice raised $21 million in Series A funding led by Transformation Capital, CEO Aris Saxena tells Axios Pro exclusively.

Other backers include Twelve Below and Virtue Ventures.

How it works: NYC-based Solstice's platform ingests clinical and compliance documents to accelerate advertising approvals for pharma clients.

AI creates draft copy, emails and ads that then are approved by humans.

It currently works with 15 pharma companies but aims for 50 by year's end, Saxena says.

Zoom out: Solstice plans to target giants like Omnicom, New Mountain Capital-backed Real Chemistry and Publicis (which last year acquired life sciences comms firm P-value Group for nearly $300 million).

State of play: Investors see an opening as pharma clients adjust to tighter DTC ad scrutiny from the Trump administration.

GTCR last year sold its stake in Klick Health to GIC and Linden Capital at a $2.5 billion EV, or 18x EBITDA.

DeepIntent, a platform helping Big Pharma buy ad space, last September raised $637 million from Vitruvian Partners.

Exclusive: Solstice raises $21M for pharma marketing

Dealmaking in pharma advertising services remains strong, despite ongoing federal scrutiny of DTC drug marketing.

Illustration of an arrow cursor stuck in a pill.

<p>Pharma marketing company Solstice raised $21 million in Series A funding led by Transformation Capital, CEO Aris Saxena tells Axios Pro exclusively.</p><ul><li>Other backers include Twelve Below and Virtue Ventures.</li></ul>

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

boulder

kansas-city

austin

chicago

dallas

detroit

washington-dc

atlanta

indianapolis

nashville

nw-arkansas

columbus

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

arapahoe

douglas

san-diego

tampa-bay

portland

cleveland

axios-local

axios-pro

axios-live

the-axios-show

Exclusive: Solstice raises $21M for pharma marketing

What to read next